Home > Insider Trading > Filing (0001209191-21-068911)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1601830	Recursion Pharmaceuticals Inc.	RXRX	Biological Products, (No Disgnostic Substances) (2836)	464099738

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1837016	Y Dean Li	C/O Recursion Pharmaceuticals 41 S. Rio Grande Street Salt Lake City UT 84101		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Disposition	2021-11-17	5,626	$20.04	1,344,374	No	4	S	Indirect	By Dean Y. Li 2021 GRAT
Class A Common Stock	Disposition	2021-11-19	13,474	$20.20	1,330,900	No	4	S	Indirect	By Dean Y. Li 2021 GRAT

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Dean Y. Li 2021 GRAT
No	4	S	Indirect	By Dean Y. Li 2021 GRAT

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Common Stock	597,263	Direct

Footnotes

Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.13 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
The Form 4 filed on November 19, 2021 inadvertently attributed the reported transaction to the incorrect holding. The original Form 4 attributed the reported transaction to the reporting person's direct holding, while the reported transaction should have been attributed to the reporting person's indirect holding by the Dean Y. Li 2021 GRAT.
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.